• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估阿尔茨海默病经济负担的主要成本驱动因素:一项结构化、快速审查。

Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review.

机构信息

Mark Connolly PhD, Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands,

出版信息

J Prev Alzheimers Dis. 2021;8(3):362-370. doi: 10.14283/jpad.2021.17.

DOI:10.14283/jpad.2021.17
PMID:34101795
Abstract

BACKGROUND

Alzheimer's Disease is the most common cause of dementia, affecting memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. AD is predicted to increase healthcare spending and costs associated with formal and informal caregiving. The aim of this study was to identify and quantify the contribution of the different cost components associated with AD.

METHODS

A structured literature review was conducted to identify studies reporting the economic burden of Alzheimer`s Disease beyond the healthcare setting. The search was conducted in Medline, Embase and EconLit and limited to studies published in the last 10 years. For each identified cost component, frequency weighted mean costs were calculated across countries to estimate the percentage contribution of each component by care setting and disease severity. Results obtained by each costing approach were also compared.

RESULTS

For community-dwelling adults, the percentage of healthcare, social care and indirect costs to total costs were 13.9%, 17.4% and 68.7%, respectively. The percentage of costs varied by disease severity with 26.0% and 10.4% of costs spent on healthcare for mild and severe disease, respectively. The proportion of total spending on indirect costs changed from 60.7% to 72.5% as disease progressed. For those in residential care, the contribution of each cost component was similar between moderate and severe disease. Social care accounted on average for 85.9% of total costs.

CONCLUSION

The contribution of healthcare costs to the overall burden was not negligible; but was generally exceeded by social and informal care costs.

摘要

背景

阿尔茨海默病是痴呆症最常见的病因,影响记忆、思维和行为。症状最终严重到足以干扰日常任务。预计阿尔茨海默病将增加医疗保健支出以及与正式和非正式护理相关的成本。本研究的目的是确定和量化与阿尔茨海默病相关的不同成本构成部分的贡献。

方法

进行了系统的文献综述,以确定报告超出医疗保健环境的阿尔茨海默病经济负担的研究。在 Medline、Embase 和 EconLit 中进行了搜索,并将搜索范围限制在过去 10 年发表的研究。对于每个确定的成本构成部分,在各国计算了频率加权平均成本,以估计每个构成部分在不同护理环境和疾病严重程度下的贡献百分比。还比较了每种成本估算方法的结果。

结果

对于居住在社区的成年人,医疗保健、社会护理和间接成本占总费用的比例分别为 13.9%、17.4%和 68.7%。疾病严重程度不同,医疗保健成本的比例也不同,轻度和重度疾病的医疗保健成本分别占 26.0%和 10.4%。随着疾病的进展,间接成本占总支出的比例从 60.7%变为 72.5%。对于居住在养老院的人,中度和重度疾病的每种成本构成部分的贡献相似。社会护理平均占总费用的 85.9%。

结论

医疗保健成本对总负担的贡献不可忽视;但通常被社会和非正式护理成本所超过。

相似文献

1
Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review.评估阿尔茨海默病经济负担的主要成本驱动因素:一项结构化、快速审查。
J Prev Alzheimers Dis. 2021;8(3):362-370. doi: 10.14283/jpad.2021.17.
2
Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.意大利阿尔茨海默病的成本和资源利用:一项观察性研究的结果。
J Prev Alzheimers Dis. 2018;5(1):55-64. doi: 10.14283/jpad.2017.31.
3
Donepezil for dementia due to Alzheimer's disease.多奈哌齐用于治疗阿尔茨海默病所致的痴呆。
Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3.
4
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.多奈哌齐、加兰他敏、利伐斯的明和美金刚治疗阿尔茨海默病的有效性和成本效果(技术评估第 111 号回顾):系统评价和经济模型。
Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.
5
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
7
Rivastigmine for Alzheimer's disease.卡巴拉汀用于治疗阿尔茨海默病。
Cochrane Database Syst Rev. 2015 Apr 10(4):CD001191. doi: 10.1002/14651858.CD001191.pub3.
8
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
9
Case management approaches to home support for people with dementia.针对痴呆症患者居家支持的个案管理方法。
Cochrane Database Syst Rev. 2015 Jan 5;1(1):CD008345. doi: 10.1002/14651858.CD008345.pub2.
10
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.阿德福韦酯与聚乙二醇化干扰素α-2a治疗慢性乙型肝炎:系统评价与经济学评估
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. doi: 10.3310/hta10280.

引用本文的文献

1
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study.血浆Aβ42/40比值、磷酸化tau181、胶质纤维酸性蛋白(GFAP)和神经丝轻链(NfL)在阿尔茨海默病和非阿尔茨海默病性痴呆连续病程中的诊断性能:一项国际多中心研究
Alzheimers Dement. 2025 Jun;21(6):e14573. doi: 10.1002/alz.14573.
2
Annual societal cost of Alzheimer's disease in Malaysia: a micro-costing approach.马来西亚阿尔茨海默病的年度社会成本:微观成本核算方法。
BMC Geriatr. 2025 Mar 6;25(1):154. doi: 10.1186/s12877-025-05717-y.
3
Time value of informal care of people with alzheimer's disease in Spain: a population-based analysis.

本文引用的文献

1
The effect of long-term care public benefits and insurance on informal care from outside the household: empirical evidence from Italy and Spain.长期护理公共福利和保险对家庭外非正式护理的影响:来自意大利和西班牙的经验证据。
Eur J Health Econ. 2020 Nov;21(8):1131-1147. doi: 10.1007/s10198-020-01215-7. Epub 2020 Jul 11.
2
Early Detection of Mild Cognitive Impairment (MCI) in Primary Care.在初级保健中早期发现轻度认知障碍(MCI)。
J Prev Alzheimers Dis. 2020;7(3):165-170. doi: 10.14283/jpad.2020.21.
3
Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
西班牙阿尔茨海默病患者非正式护理的时间价值:一项基于人群的分析。
Eur J Health Econ. 2025 Apr;26(3):377-402. doi: 10.1007/s10198-024-01713-y. Epub 2024 Aug 9.
4
Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.使用患者-照顾者二元调查评估阿尔茨海默病连续体中的生活质量、经济负担和独立性。
J Alzheimers Dis. 2024;99(1):191-206. doi: 10.3233/JAD-231259.
5
Exploring the relationship between patient-relevant outcomes and Alzheimer's disease progression assessed using the clinical dementia rating scale: a systematic literature review.探索使用临床痴呆评定量表评估的与患者相关的结局与阿尔茨海默病进展之间的关系:一项系统文献综述。
Front Neurol. 2023 Aug 17;14:1208802. doi: 10.3389/fneur.2023.1208802. eCollection 2023.
6
Modelling the Pan-European Economic Burden of Alzheimer's Disease.模拟阿尔茨海默病在泛欧洲地区的经济负担。
JAR Life. 2022 Nov 15;11:38-46. doi: 10.14283/jarlife.2022.7. eCollection 2022.
7
Mediation Analysis and Mixed-Effects Models for the Identification of Stage-specific Imaging Genetics Patterns in Alzheimer's Disease.用于识别阿尔茨海默病阶段特异性影像遗传学模式的中介分析和混合效应模型
Proceedings (IEEE Int Conf Bioinformatics Biomed). 2022 Dec;2022:2667-2673. doi: 10.1109/bibm55620.2022.9995405.
8
Protective effect of irisin against Alzheimer's disease.鸢尾素对阿尔茨海默病的保护作用。
Front Psychiatry. 2022 Sep 20;13:967683. doi: 10.3389/fpsyt.2022.967683. eCollection 2022.
9
Contribution of Iranian researchers in Alzheimer's disease research: A 10 years scientometric analysis.伊朗研究人员在阿尔茨海默病研究中的贡献:一项为期10年的科学计量分析。
J Diabetes Metab Disord. 2021 Nov 4;20(2):2025-2036. doi: 10.1007/s40200-021-00929-6. eCollection 2021 Dec.
美国早期阿尔茨海默病的成本:一项前瞻性队列研究(GERAS-US)的横断面分析 1 。
J Alzheimers Dis. 2020;75(2):437-450. doi: 10.3233/JAD-191212.
4
Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.日本社区居住的阿尔茨海默病患者的成本和资源利用:前瞻性观察 GERAS-J 研究的基线结果。
J Alzheimers Dis. 2020;74(1):127-138. doi: 10.3233/JAD-190811.
5
Informal caring for back pain: overlooked costs of back pain and projections to 2030.非正规护理腰痛:被忽视的腰痛成本和到 2030 年的预测。
Pain. 2020 May;161(5):1012-1018. doi: 10.1097/j.pain.0000000000001788.
6
Associated Factors of Total Costs of Alzheimer's Disease: A Cluster-Randomized Observational Study in China.阿尔茨海默病总成本的相关因素:一项在中国进行的整群随机观察性研究
J Alzheimers Dis. 2019;69(3):795-806. doi: 10.3233/JAD-190166.
7
Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.与阿尔茨海默病痴呆进展过程中对非正式照护者的长期影响相关的因素:来自 GERAS 的 36 个月结果。
Int Psychogeriatr. 2020 Feb;32(2):267-277. doi: 10.1017/S1041610219000425. Epub 2019 May 28.
8
The economic value of time of informal care and its determinants (The CUIDARSE Study).非正式护理时间的经济价值及其决定因素(CUIDARSE 研究)。
PLoS One. 2019 May 21;14(5):e0217016. doi: 10.1371/journal.pone.0217016. eCollection 2019.
9
The hidden cost of informal care: An empirical study on female caregivers' subjective well-being.非正式护理的隐性成本:女性护理者主观幸福感的实证研究。
Soc Sci Med. 2019 Mar;224:85-93. doi: 10.1016/j.socscimed.2019.01.051. Epub 2019 Feb 7.
10
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.全球、区域和国家阿尔茨海默病及其他类型痴呆症负担,1990-2016 年:2016 年全球疾病负担研究的系统分析。
Lancet Neurol. 2019 Jan;18(1):88-106. doi: 10.1016/S1474-4422(18)30403-4. Epub 2018 Nov 26.